Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 4/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725553 | 0.88 | IDH1 (0.69) | IDH1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL4124525 | 0.86 | NTRK1 (0.55) | RAB9AMAPTMEN1KMT2ANPC1 | |
| SCHEMBL13556605 | 0.85 | RAB9A (0.65) | IDH1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL4121749 | 0.83 | RAB9A (0.67) | IDH1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL4116578 | 0.81 | MEN1 (0.70) | RAB9AMAPTMEN1KMT2ANPC1 | |
| SCHEMBL4105985 | 0.81 | RAB9A (0.68) | IDH1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL4118595 | 0.81 | IDH1 (0.58) | IDH1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL13853016 | 0.81 | HTT (0.58) | RAB9AMAPTMEN1KMT2ANPC1 | |
| SCHEMBL14561170 | 0.80 | RAB9A (0.67) | RAB9AMAPTMEN1KMT2ANPC1 | |
| SCHEMBL4548133 | 0.80 | MEN1 (0.61) | IDH1RAB9AMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | claimed |
| EP-1804785-A2 | DIARYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2007-07-11 | — | — | EP | claimed |
| WO-2006049941-A2 | DIARYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-05-11 | — | — | WO | claimed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | IDH1 666/4885EGFR 772/4885RAB9A 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.